Netherlands

Netherlands

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.87 (0.70 - 1.04) 2019 Modelled IHME
0.88 (0.71 - 1.05) 2018 Modelled IHME
0.9 (0.72 - 1.07) 2017 Modelled IHME
0.91 (0.75 - 1.08) 2016 Modelled IHME
0.92 (0.77 - 1.09) 2015 Modelled IHME
0.92 (0.76 - 1.08) 2014 Modelled IHME
0.92 (0.76 - 1.08) 2013 Modelled IHME
0.91 (0.75 - 1.08) 2012 Modelled IHME
0.91 (0.75 - 1.08) 2011 Modelled IHME
0.91 (0.73 - 1.08) 2010 Modelled IHME
0.9 (0.74 - 1.07) 2009 Modelled IHME
0.9 (0.74 - 1.06) 2008 Modelled IHME
0.89 (0.74 - 1.05) 2007 Modelled IHME
0.89 (0.73 - 1.05) 2006 Modelled IHME
0.89 (0.73 - 1.05) 2005 Modelled IHME
0.89 (0.74 - 1.05) 2004 Modelled IHME
0.9 (0.75 - 1.06) 2003 Modelled IHME
0.91 (0.76 - 1.08) 2002 Modelled IHME
0.92 (0.77 - 1.09) 2001 Modelled IHME
0.93 (0.77 - 1.10) 2000 Modelled IHME
0.93 (0.77 - 1.10) 1999 Modelled IHME
0.92 (0.76 - 1.09) 1998 Modelled IHME
0.92 (0.76 - 1.09) 1997 Modelled IHME
0.91 (0.76 - 1.08) 1996 Modelled IHME
0.91 (0.75 - 1.09) 1995 Modelled IHME
0.91 (0.76 - 1.08) 1994 Modelled IHME
0.92 (0.75 - 1.09) 1993 Modelled IHME
0.92 (0.76 - 1.09) 1992 Modelled IHME
0.93 (0.77 - 1.11) 1991 Modelled IHME
0.94 (0.77 - 1.13) 1990 Modelled IHME
0.34 (0.22 - 0.47) 2016 Survey/reported Koopsen J et al, 2019
0.2 (0.10 - 0.40) 2007 Survey/reported Hahne SJM et al, 2012
0.09 (0.07 - 0.11) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.06 (0.04 - 0.07) 2019 Modelled IHME
0.06 (0.04 - 0.08) 2018 Modelled IHME
0.06 (0.04 - 0.08) 2017 Modelled IHME
0.07 (0.05 - 0.09) 2016 Modelled IHME
0.08 (0.06 - 0.11) 2015 Modelled IHME
0.12 (0.08 - 0.16) 2014 Modelled IHME
0.18 (0.12 - 0.24) 2013 Modelled IHME
0.25 (0.17 - 0.34) 2012 Modelled IHME
0.31 (0.21 - 0.43) 2011 Modelled IHME
0.34 (0.22 - 0.47) 2010 Modelled IHME
0.34 (0.23 - 0.46) 2009 Modelled IHME
0.34 (0.23 - 0.46) 2008 Modelled IHME
0.34 (0.23 - 0.45) 2007 Modelled IHME
0.34 (0.23 - 0.45) 2006 Modelled IHME
0.34 (0.23 - 0.44) 2005 Modelled IHME
0.35 (0.24 - 0.46) 2004 Modelled IHME
0.37 (0.25 - 0.49) 2003 Modelled IHME
0.4 (0.27 - 0.52) 2002 Modelled IHME
0.42 (0.28 - 0.55) 2001 Modelled IHME
0.43 (0.28 - 0.56) 2000 Modelled IHME
0.43 (0.28 - 0.56) 1999 Modelled IHME
0.42 (0.27 - 0.56) 1998 Modelled IHME
0.42 (0.27 - 0.56) 1997 Modelled IHME
0.42 (0.27 - 0.56) 1996 Modelled IHME
0.42 (0.27 - 0.55) 1995 Modelled IHME
0.42 (0.27 - 0.55) 1994 Modelled IHME
0.42 (0.27 - 0.55) 1993 Modelled IHME
0.42 (0.27 - 0.55) 1992 Modelled IHME
0.42 (0.28 - 0.56) 1991 Modelled IHME
0.43 (0.29 - 0.58) 1990 Modelled IHME
0.04 (0.03 - 0.05) 2015 Modelled WHO
Showing out of
Show more
Men who have sex with men (MSM)
Download
Value (%) Year Type Source
0.48 2017 Survey/reported ECDC Monitoring Report
0.83 2017 Survey/reported ECDC Monitoring Report
Showing out of
Show more
Pregnant women
Download
Value (%) Year Type Source
0.3 (0.30 - 0.40) 2016 Modelled ECDC
0.3 (0.30 - 0.40) 2006 Survey/reported Op de Coul EL et al, 2011
0.3 (0.30 - 0.40) 2007 Survey/reported Op de Coul EL et al, 2011
0.4 (0.40 - 0.40) 2008 Survey/reported Op de Coul EL et al, 2011
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
11 (8 - 16) 2019 Modelled IHME
11 (8 - 16) 2018 Modelled IHME
11 (8 - 16) 2017 Modelled IHME
11 (8 - 16) 2016 Modelled IHME
11 (8 - 16) 2015 Modelled IHME
12 (8 - 17) 2014 Modelled IHME
12 (8 - 17) 2013 Modelled IHME
12 (8 - 17) 2012 Modelled IHME
12 (8 - 17) 2011 Modelled IHME
12 (8 - 17) 2010 Modelled IHME
12 (8 - 17) 2009 Modelled IHME
12 (8 - 17) 2008 Modelled IHME
12 (8 - 17) 2007 Modelled IHME
12 (8 - 17) 2006 Modelled IHME
12 (8 - 17) 2005 Modelled IHME
12 (8 - 17) 2004 Modelled IHME
12 (8 - 17) 2003 Modelled IHME
12 (8 - 17) 2002 Modelled IHME
12 (8 - 17) 2001 Modelled IHME
12 (9 - 17) 2000 Modelled IHME
12 (9 - 17) 1999 Modelled IHME
12 (9 - 17) 1998 Modelled IHME
12 (9 - 17) 1997 Modelled IHME
12 (9 - 18) 1996 Modelled IHME
12 (9 - 18) 1995 Modelled IHME
12 (9 - 18) 1994 Modelled IHME
12 (9 - 18) 1993 Modelled IHME
12 (9 - 18) 1992 Modelled IHME
12 (9 - 18) 1991 Modelled IHME
12 (9 - 18) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
92 2018 Survey/reported WHO/UNICEF
92 2017 Survey/reported WHO/UNICEF
93 2016 Survey/reported WHO/UNICEF
94 2015 Survey/reported WHO/UNICEF
94 2014 Survey/reported WHO/UNICEF
51 2013 Survey/reported WHO/UNICEF
20 2012 Survey/reported WHO/UNICEF
20 2011 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
414 (170 - 659) 2014 Survey/reported van Laar M et al, 2014
HBV National Action Plan
HBV elimination goal
HBV testing policy
Pregnant women, Risk-based
HepB birth dose policy
Yes (for risk groups)
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Some (11-30%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.48 (0.40 - 0.59) 2019 Modelled IHME
0.48 (0.39 - 0.58) 2018 Modelled IHME
0.47 (0.39 - 0.58) 2017 Modelled IHME
0.47 (0.38 - 0.57) 2016 Modelled IHME
0.46 (0.38 - 0.56) 2015 Modelled IHME
0.44 (0.36 - 0.53) 2014 Modelled IHME
0.4 (0.32 - 0.48) 2013 Modelled IHME
0.35 (0.29 - 0.42) 2012 Modelled IHME
0.32 (0.26 - 0.38) 2011 Modelled IHME
0.3 (0.25 - 0.36) 2010 Modelled IHME
0.3 (0.25 - 0.36) 2009 Modelled IHME
0.31 (0.25 - 0.37) 2008 Modelled IHME
0.31 (0.26 - 0.37) 2007 Modelled IHME
0.32 (0.27 - 0.38) 2006 Modelled IHME
0.33 (0.28 - 0.39) 2005 Modelled IHME
0.36 (0.30 - 0.43) 2004 Modelled IHME
0.42 (0.34 - 0.50) 2003 Modelled IHME
0.48 (0.39 - 0.58) 2002 Modelled IHME
0.53 (0.42 - 0.65) 2001 Modelled IHME
0.55 (0.44 - 0.68) 2000 Modelled IHME
0.54 (0.43 - 0.66) 1999 Modelled IHME
0.5 (0.41 - 0.62) 1998 Modelled IHME
0.47 (0.38 - 0.57) 1997 Modelled IHME
0.43 (0.35 - 0.53) 1996 Modelled IHME
0.41 (0.34 - 0.51) 1995 Modelled IHME
0.41 (0.33 - 0.50) 1994 Modelled IHME
0.4 (0.33 - 0.49) 1993 Modelled IHME
0.4 (0.33 - 0.49) 1992 Modelled IHME
0.4 (0.32 - 0.49) 1991 Modelled IHME
0.4 (0.32 - 0.49) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
0.16 (0.06 - 0.27) 2019 Survey/reported Koopsen J et al, 2019
0.1 (0 - 0.20) 2007 Survey/reported Vriend HJ et al, 2013
0.2 (0.10 - 0.40) 2014 Modelled Gower et al, 2014
Showing out of
Show more
Men who have sex with men (MSM)
Download
Value (%) Year Type Source
1.3 (0.80 - 1.90) 2003 Survey/reported van de Laar TJ et al , 2007
0.7 (0.10 - 1.90) 2007 Survey/reported Van Rooijen MS et al , 2013
4.8 2017 Survey/reported ECDC
Showing out of
Show more
People who inject drugs (PWID)
Download
Value (%) Year Type Source
55.3 (49.70 - 60.90) 2017 Modelled Degenhardt L et al, 2017
39.3 2013 Survey/reported EMCDDA
Showing out of
Show more

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
35 (27 - 44) 2019 Modelled IHME
35 (26 - 44) 2018 Modelled IHME
35 (26 - 44) 2017 Modelled IHME
35 (26 - 44) 2016 Modelled IHME
35 (26 - 43) 2015 Modelled IHME
35 (26 - 43) 2014 Modelled IHME
34 (26 - 43) 2013 Modelled IHME
34 (26 - 43) 2012 Modelled IHME
34 (26 - 43) 2011 Modelled IHME
34 (26 - 42) 2010 Modelled IHME
34 (26 - 42) 2009 Modelled IHME
34 (26 - 42) 2008 Modelled IHME
34 (26 - 42) 2007 Modelled IHME
34 (26 - 42) 2006 Modelled IHME
34 (26 - 42) 2005 Modelled IHME
34 (26 - 42) 2004 Modelled IHME
34 (25 - 42) 2003 Modelled IHME
34 (25 - 42) 2002 Modelled IHME
34 (25 - 42) 2001 Modelled IHME
34 (25 - 42) 2000 Modelled IHME
34 (25 - 42) 1999 Modelled IHME
34 (26 - 42) 1998 Modelled IHME
34 (26 - 42) 1997 Modelled IHME
34 (26 - 42) 1996 Modelled IHME
34 (25 - 42) 1995 Modelled IHME
34 (26 - 42) 1994 Modelled IHME
34 (25 - 43) 1993 Modelled IHME
34 (25 - 43) 1992 Modelled IHME
34 (26 - 43) 1991 Modelled IHME
34 (25 - 43) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (170 - 659) 2014 Survey/reported van Laar M et al, 2014
HBV National Action Plan
HBV elimination goal
HBV testing policy
Pregnant women, Risk-based
HepB birth dose policy
Yes (for risk groups)
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Some (11-30%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
0.87 (%)
2019
(0.7 - 1.04(%))
IHME
HCV (RNA/cAg+)
0.48 (%)
2019
(0.4 - 0.59(%))
IHME

Survey/surveillance

HBV (HBsAg+)
0.34 (%)
2016
(0.22 - 0.47(%))
Koopsen J et al, 2019
HCV (anti-HCV)
0.16 (%)
2019
(0.06 - 0.27(%))
Koopsen J et al, 2019

Hepatitis related deaths (national)

Modelled

HBV
283
2019
(218 - 362)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
621
2019
(491 - 760)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.06 (%)
2019, latest modelled
(0.04 - 0.07(%))
IHME

Prevalence PWID

HCV
39.30 (%)
2013, survey/surveillance
EMCDDA

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
414
2014
(170 - 659)
van Laar M et al, 2014
Eligible for HBV generic medicines
Eligible for HCV generic medicines

Resources